Relationships of lipocalin 2 with breast tumorigenesis and metastasis

Journal of Cellular Physiology

Volumn 226, Issue 2, 2011, Pages 309-314

  Leng, Xiaohong ^a   Wu, Yun ^a   Arlinghaus, Ralph B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; GELATINASE B; IRON; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

BREAST CANCER; BREAST METASTASIS; CARCINOGENESIS; HOMEOSTASIS; HUMAN; LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; TUMOR GROWTH;

ACUTE-PHASE PROTEINS; ANIMALS; BREAST NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; IRON; LEUKEMIA; LIPOCALINS; MATRIX METALLOPROTEINASE 9; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 78649641929     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22403     Document Type: Review

References (48)

1. Arlinghaus R, Leng X. 2008. Requirement of lipocalin 2 for chronic myeloid leukemia. Leuk Lymphoma 49(4): 600-603.
2. Aslakson CJ, Miller FR. 1992. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52(6): 1399-1405.
3. Bao G, Clifton M, Hoette TM, Mori K, Deng SX, Qiu A, Viltard M, Williams D, Paragas N, Leete T, Kulkarni R, Li X, Lee B, Kalandadze A, Ratner AJ, Pizarro JC, Schmidt-Ott KM, Landry DW, Raymond KN, Strong RK, Barasch J. 2010. Iron traffics in circulation bound to a siderocalin (Ngal)-catechol complex. Nat Chem Biol 6(8): 602-609.
4. Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maass N, Friedl A. 2008. Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat 108(3): 389-397.
5. Berger T, Togawa A, Duncan GS, Elia AJ, You-Ten A, Wakeham A, Fong HE, Cheung CC, Mak TW. 2006. Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc Natl Acad Sci USA 103(6): 1834-1839.
6. Berger T, Cheung CC, Elia AJ, Mak TW. 2010. Disruption of the Lcn2 gene in mice suppresses primary mammary tumor formation but does not decrease lung metastasis. Proc Natl Acad Sci USA 107(7): 2995-3000.
7. Davidson B, Reich R, Risberg B, Nesland JM. 2002. The biological role and regulation of matrix metalloproteinases (MMP) in cancer. Arkh Patol 64(3): 47-53.
8. Devarajan P. 2007. Neutrophil gelatinase-associated lipocalin: New paths for an old shuttle. Cancer Ther 5: (B): 463-470.
9. Devireddy LR, Teodoro JG, Richard FA, Green MR. 2001. Induction of apoptosis by a secreted lipocalin that is transcriptionally regulated by IL-3 deprivation. Science 293(5531): 829-834.
10. Devireddy LR, Gazin C, Zhu X, Green MR. 2005. A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 123(7): 1293-1305.
11. Devireddy LR, Hart DO, Goetz DH, Green MR. 2010. A mammalian siderophore synthesized by an enzyme with a bacterial homolog involved in enterobactin production. Cell 141(6): 1006-1017.
12. Emerit J, Beaumont C, Trivin F. 2001. Iron metabolism, free radicals, and oxidative injury. Biomed Pharmacother 55(6): 333-339.
13. Fernandez CA, Yan L, Louis G, Yang J, Kutok JL, Moses MA. 2005. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 11(15): 5390-5395.
14. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, Akira S, Aderem A. 2004. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 432(7019): 917-921.
15. Flower DR, North AC, Sansom CE. 2000. The lipocalin protein family: Structural and sequence overview. Biochim Biophys Acta 1482(1-2): 9-24.
16. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK. 2002. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 10(5): 1033-1043.
17. Hanai J, Mammoto T, Seth P, Mori K, Karumanchi SA, Barasch J, Sukhatme VP. 2005. Lipocalin 2 diminishes invasiveness and metastasis of Ras-transformed cells. J Biol Chem 280(14): 13641-13647.
18. Hann HW, Stahlhut MW, Blumberg BS. 1988. Iron nutrition and tumor growth: Decreased tumor growth in iron-deficient mice. Cancer Res 48(15): 4168-4170.
19. Hraba-Renevey S, Turler H, Kress M, Salomon C, Weil R. 1989. SV40-induced expression of mouse gene 24p3 involves a post-transcriptional mechanism. Oncogene 4(5): 601-608.
20. Huang X. 2008. Does iron have a role in breast cancer? Lancet Oncol 9(8): 803-807.
21. Hvidberg V, Jacobsen C, Strong RK, Cowland JB, Moestrup SK, Borregaard N. 2005. The endocytic receptor megalin binds the iron transporting neutrophil-gelatinase-associated lipocalin with high affinity and mediates its cellular uptake. FEBS Lett 579(3): 773-777.
22. Kessenbrock K, Plaks V, Werb Z. 2010. Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell 141(1): 52-67.
23. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. 1993. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 268(14): 10425-10432.
24. Kubben FJ, Sier CF, Hawinkels LJ, Tschesche H, van Duijn W, Zuidwijk K, van der Reijden JJ, Hanemaaijer R, Griffioen G, Lamers CB, Verspaget HW. 2007. Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur J Cancer 43(12): 1869-1876.
25. Leng X, Lin H, Ding T, Wang Y, Wu Y, Klumpp S, Sun T, Zhou Y, Monaco P, Belmont J, Aderem A, Akira S, Strong R, Arlinghaus R. 2008. Lipocalin 2 is required for BCR-ABL-induced tumorigenesis. Oncogene 27(47): 6110-6119.
26. Leng X, Ding T, Lin H, Wang Y, Hu L, Hu J, Feig B, Zhang W, Pusztai L, Symmans WF, Wu Y, Arlinghaus RB. 2009. Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res 69(22): 8579-8584.
27. Li SH, Hawthorne VS, Neal CL, Sanghera S, Xu J, Yang J, Guo H, Steeg PS, Yu D. 2009. Upregulation of neutrophil gelatinase-associated lipocalin by ErbB2 through nuclear factor-kappaB activation. Cancer Res 69(24): 9163-9168.
28. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, Pollard JW. 2003. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163(5): 2113-2126.
29. Lin H, Monaco G, Sun T, Ling X, Stephens C, Xie S, Belmont J, Arlinghaus R. 2005. Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia. Oncogene 24(20): 3246-3256.
30. Liu Q, Nilsen-Hamilton M. 1995. Identification of a new acute phase protein. J Biol Chem 270(38): 22565-22570.
31. Moore AB, Shannon J, Chen C, Lampe JW, Ray RM, Lewis SK, Lin M, Stalsberg H, Thomas DB. 2009. Dietary and stored iron as predictors of breast cancer risk: A nested case-control study in Shanghai. Int J Cancer 125(5): 1110-1117.
32. Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J, Schmidt-Ott KM, Chen X, Li JY, Weiss S, Mishra J, Cheema FH, Markowitz G, Suganami T, Sawai K, Mukoyama M, Kunis C, D'Agati V, Devarajan P, Barasch J. 2005. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 115(3): 610-621.
33. Nickolas TL, Barasch J, Devarajan P. 2008. Biomarkers in acute and chronic kidney disease. Curr Opin Nephrol Hypertens 17(2): 127-132.
34. Rao VA, Klein SR, Agama KK, Toyoda E, Adachi N, Pommier Y, Shacter EB. 2009. The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells. Cancer Res 69(3): 948-957.
35. Ryon J, Bendickson L, Nilsen-Hamilton M. 2002. High expression in involuting reproductive tissues of uterocalin/24p3, a lipocalin and acute phase protein. Biochem J 367(Pt 1): 271-277.
36. Seth P, Porter D, Lahti-Domenici J, Geng Y, Richardson A, Polyak K. 2002. Cellular and molecular targets of estrogen in normal human breast tissue. Cancer Res 62(16): 4540-4544.
37. Sheng Z, Wang SZ, Green MR. 2009. Transcription and signalling pathways involved in BCR-ABL-mediated misregulation of 24p3 and 24p3R. EMBO J 28(7): 866-876.
38. Shi H, Gu Y, Yang J, Xu L, Mi W, Yu W. 2008. Lipocalin 2 promotes lung metastasis of murine breast cancer cells. J Exp Clin Cancer Res 27: 83.
39. Stoesz SP, Gould MN. 1995. Overexpression of neu-related lipocalin (NRL) in neu-initiated but not ras or chemically initiated rat mammary carcinomas. Oncogene 11(11): 2233-2241.
40. Stoesz SP, Friedl A, Haag JD, Lindstrom MJ, Clark GM, Gould MN. 1998. Heterogeneous expression of the lipocalin NGAL in primary breast cancers. Int J Cancer 79(6): 565-572.
41. Triebel S, Blaser J, Reinke H, Tschesche H. 1992. A 25kDa alpha 2-microglobulin-related protein is a component of the 125kDa form of human gelatinase. FEBS Lett 314(3): 386-388.
42. Tschesche H, Zolzer V, Triebel S, Bartsch S. 2001. The human neutrophil lipocalin supports the allosteric activation of matrix metalloproteinases. Eur J Biochem 268(7): 1918-1928.
43. Xu SY, Carlson M, Engstrom A, Garcia R, Peterson CG, Venge P. 1994. Purification and characterization of a human neutrophil lipocalin (HNL) from the secondary granules of human neutrophils. Scand J Clin Lab Invest 54(5): 365-376.
44. Yan L, Borregaard N, Kjeldsen L, Moses MA. 2001. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 276(40): 37258-37265.
45. Yan QW, Yang Q, Mody N, Graham TE, Hsu CH, Xu Z, Houstis NE, Kahn BB, Rosen ED. 2007. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes 56(10): 2533-2540.
46. Yang J, Moses MA. 2009. Lipocalin 2: A multifaceted modulator of human cancer. Cell Cycle 8(15): 2347-2352.
47. Yang J, Goetz D, Li JY, Wang W, Mori K, Setlik D, Du T, Erdjument-Bromage H, Tempst P, Strong R, Barasch J. 2002. An iron delivery pathway mediated by a lipocalin. Mol Cell 10(5): 1045-1056.
48. Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton MC, Kung AL, Strong RK, Zurakowski D, Moses MA. 2009. Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci USA 106(10): 3913-3918.